2.45
price down icon3.16%   -0.08
after-market 시간 외 거래: 2.45
loading
전일 마감가:
$2.53
열려 있는:
$2.55
하루 거래량:
8.20M
Relative Volume:
0.53
시가총액:
$886.54M
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-1.4671
EPS:
-1.67
순현금흐름:
$-400.48M
1주 성능:
-5.77%
1개월 성능:
-21.73%
6개월 성능:
-54.21%
1년 성능:
-79.41%
1일 변동 폭
Value
$2.43
$2.5891
1주일 범위
Value
$2.43
$2.76
52주 변동 폭
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
명칭
Iovance Biotherapeutics Inc
Name
전화
(650) 260-7120
Name
주소
825 INDUSTRIAL ROAD, SAN CARLOS
Name
직원
838
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
IOVA's Discussions on Twitter

IOVA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
2.45 904.63M 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
387.18 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.65 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
451.20 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
708.09 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
308.91 37.96B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-15 다운그레이드 Goldman Neutral → Sell
2025-05-16 다운그레이드 UBS Buy → Neutral
2025-05-12 다운그레이드 Truist Buy → Hold
2025-05-09 다운그레이드 Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 개시 UBS Buy
2024-07-29 다운그레이드 Piper Sandler Overweight → Neutral
2023-11-20 개시 Goldman Buy
2023-09-18 재확인 Barclays Overweight
2023-05-30 업그레이드 Wells Fargo Equal Weight → Overweight
2023-03-27 재개 Wells Fargo Equal Weight
2023-01-27 업그레이드 Piper Sandler Neutral → Overweight
2022-12-09 다운그레이드 Goldman Buy → Neutral
2022-10-31 개시 Guggenheim Neutral
2022-08-18 재개 Wells Fargo Equal Weight
2022-01-28 업그레이드 Stifel Hold → Buy
2021-12-07 재개 Cowen Outperform
2021-06-10 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 다운그레이드 Piper Sandler Overweight → Neutral
2021-05-19 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 다운그레이드 Stifel Buy → Hold
2021-05-03 개시 Truist Buy
2021-04-16 개시 Goldman Buy
2021-03-08 업그레이드 H.C. Wainwright Neutral → Buy
2020-12-15 다운그레이드 H.C. Wainwright Buy → Neutral
2020-10-06 다운그레이드 Wells Fargo Overweight → Equal Weight
2020-04-22 개시 Mizuho Buy
2020-03-04 개시 Barclays Overweight
2020-02-26 재확인 H.C. Wainwright Buy
2020-02-26 재확인 Oppenheimer Outperform
2019-12-18 개시 JMP Securities Mkt Outperform
2019-10-01 개시 Stifel Buy
2019-04-29 개시 Piper Jaffray Overweight
2019-02-28 재확인 Chardan Capital Markets Buy
2019-02-07 개시 Robert W. Baird Outperform
2018-12-31 재개 B. Riley FBR Buy
2018-07-06 재확인 Chardan Capital Markets Buy
2018-04-10 업그레이드 B. Riley FBR, Inc. Neutral → Buy
2018-03-13 재확인 B. Riley FBR, Inc. Neutral
2018-02-23 다운그레이드 B. Riley FBR, Inc. Buy → Neutral
2018-01-25 재확인 H.C. Wainwright Buy
2017-11-01 재확인 B. Riley FBR, Inc. Buy
모두보기

Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스

pulisher
Aug 20, 2025

Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025 - CGTLive®

Aug 20, 2025
pulisher
Aug 19, 2025

Iovance Biotherapeutics Gains Health Canada Approval - MSN

Aug 19, 2025
pulisher
Aug 19, 2025

Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations - 28/22 News

Aug 19, 2025
pulisher
Aug 19, 2025

Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada - CGTLive®

Aug 19, 2025
pulisher
Aug 19, 2025

Unexpected Surge: Analyzing Iovance’s Performance - StocksToTrade

Aug 19, 2025
pulisher
Aug 19, 2025

Why Iovance Biotherapeutics Stock Was Climbing Today - Mitrade

Aug 19, 2025
pulisher
Aug 19, 2025

Why Iovance Biotherapeutics Stock Was Climbing Today - The Motley Fool

Aug 19, 2025
pulisher
Aug 19, 2025

Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ - Stocktwits

Aug 19, 2025
pulisher
Aug 19, 2025

Iovance Stock Soars 21.2% on Amtagvi Approval - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Iovance gets conditional Health Canada approval for Amtagvi - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Health Canada approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com India

Aug 18, 2025
pulisher
Aug 18, 2025

Iovance Says Amtagvi Gets Health Canada Clearance for Advanced Melanoma - MarketScreener

Aug 18, 2025
pulisher
Aug 18, 2025

Health Canada approves Iovance’s Amtagvi for advanced melanoma - Investing.com

Aug 18, 2025
pulisher
Aug 18, 2025

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - The Manila Times

Aug 18, 2025
pulisher
Aug 18, 2025

Iovance Biotherapeutics Receives Health Canada Approval for Amtagvi® T Cell Therapy for Advanced Melanoma - Quiver Quantitative

Aug 18, 2025
pulisher
Aug 18, 2025

Iovance's Amtagvi receives Health Canada approval for advanced melanoma - MarketScreener

Aug 18, 2025
pulisher
Aug 18, 2025

First-Ever T Cell Therapy for Solid Tumors: Iovance's Amtagvi Gets Historic Canada Approval - Stock Titan

Aug 18, 2025
pulisher
Aug 18, 2025

Wells Fargo Lowers Price Target for Iovance Biotherapeutics (IOVA) Amid Mixed Q2 Results: Is Amtagvi's Growth Enough to Justify the Downgrade? - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth - Yahoo Finance

Aug 17, 2025
pulisher
Aug 16, 2025

Is Iovance Biotherapeutics Inc. a momentum stock2025 Stock Rankings & Safe Capital Growth Plans - thegnnews.com

Aug 16, 2025
pulisher
Aug 15, 2025

Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Iovance Biotherapeutics shares rise 2.04% premarket as private investment in oncology ventures surges. - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Iovance Biotherapeutics shares rise 3.27% intraday as private investment in oncology ventures surges. - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Iovance Biotherapeutics' Earnings Call Highlights Growth, Revenue Up 22% to $60M - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Iovance Biotherapeutics’ Earnings Call Highlights Growth - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve

Aug 12, 2025
pulisher
Aug 12, 2025

Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade

Aug 12, 2025
pulisher
Aug 12, 2025

Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com

Aug 12, 2025
pulisher
Aug 12, 2025

AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈

Aug 12, 2025
pulisher
Aug 11, 2025

Published on: 2025-08-12 06:23:53 - beatles.ru

Aug 11, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛

Aug 09, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 09, 2025

Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail

Aug 09, 2025
pulisher
Aug 09, 2025

How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade

Aug 09, 2025
pulisher
Aug 09, 2025

Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com

Aug 08, 2025
pulisher
Aug 08, 2025

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com

Aug 08, 2025

Iovance Biotherapeutics Inc (IOVA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Iovance Biotherapeutics Inc 주식 (IOVA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Puri Raj K.
Chief Regulatory Officer
Jun 02 '25
Option Exercise
0.00
5,469
0
212,321
Vogt Frederick G
Interim CEO & General Counsel
Jun 02 '25
Option Exercise
0.00
52,085
0
426,731
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 02 '25
Option Exercise
0.00
12,695
0
105,608
BILINSKY IGOR
Chief Operating Officer
Jun 02 '25
Option Exercise
0.00
12,305
0
99,883
Bellemin Jean-Marc
Chief Financial Officer
Jun 02 '25
Option Exercise
0.00
8,789
0
64,993
Puri Raj K.
Chief Regulatory Officer
May 23 '25
Buy
1.74
5,600
9,743
206,852
Vogt Frederick G
Interim CEO & General Counsel
May 14 '25
Buy
1.69
25,000
42,250
374,646
Puri Raj K.
Chief Regulatory Officer
Mar 14 '25
Option Exercise
0.00
8,334
0
203,761
Bellemin Jean-Marc
Chief Financial Officer
Mar 03 '25
Option Exercise
0.00
58,590
0
87,938
BILINSKY IGOR
Chief Operating Officer
Mar 03 '25
Option Exercise
0.00
62,106
0
120,880
$24.54
price up icon 0.95%
$84.00
price down icon 0.90%
$26.98
price up icon 2.70%
$104.79
price down icon 0.27%
$132.17
price up icon 3.00%
biotechnology ONC
$308.91
price up icon 0.09%
자본화:     |  볼륨(24시간):